Department of Biophysics, All India Institute of Medical Sciences, New Delhi, India.
Clin Transl Oncol. 2013 Nov;15(11):969-73. doi: 10.1007/s12094-013-1031-3. Epub 2013 Apr 4.
Solid tumors involve an inflammatory microenvironment portrayed by immune cells playing role in cancer progression via inflammatory p38α mitogen-activated protein kinase (MAPK) molecule that produces pro-inflammatory cytokines-TNFα, IL1β and IL6. This study quantified and compared the expression of p38α in peripheral blood mononuclear cells (PBMCs) of HNSCC patients with the healthy subjects.
The PBMC were isolated from the 35 control and 83 HNSCC patients. The expression of p38α in PBMCs was assessed using surface plasmon resonance (SPR), ELISA and western blot analysis.
p38α levels were found to be over-expressed in HNSCC patients 0.98 ng/μl (95 % CI 0.95-1.02) as compared to controls 0.46 ng/μl (95 % CI 0.42-0.50) (p < 0.0001).
p38α is over-expressed in PBMCs of HNSCC patients and may play a role in the progression of cancer. This research may translate a protein marker for HNSCC to clinical oncologist for therapeutic intervention and use as a predictive marker.
实体瘤涉及由免疫细胞组成的炎症微环境，这些细胞通过炎症 p38α 丝裂原活化蛋白激酶 (MAPK) 分子在癌症进展中发挥作用，该分子产生促炎细胞因子-TNFα、IL1β 和 IL6。本研究定量比较了 HNSCC 患者和健康受试者外周血单个核细胞 (PBMC) 中 p38α 的表达。
从 35 名对照和 83 名 HNSCC 患者中分离 PBMC。使用表面等离子体共振 (SPR)、ELISA 和 Western blot 分析评估 PBMC 中 p38α 的表达。
与对照组 0.46 ng/μl（95%CI 0.42-0.50）相比，HNSCC 患者的 p38α 水平为 0.98 ng/μl（95%CI 0.95-1.02），表达过度（p<0.0001）。
p38α 在 HNSCC 患者的 PBMC 中过度表达，可能在癌症进展中发挥作用。这项研究可能为临床肿瘤学家转化 HNSCC 的蛋白标志物用于治疗干预和作为预测标志物。
